Loading stock data…
NNVC
$1.30+0.06 (+4.84%)
Market ClosedLast close May 1
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
NanoViricides, Inc. in the Healthcare sector is trading at $1.30. The stock is currently 42% below its 52-week high of $2.23, remaining 0.0% below its 200-day moving average. Technical signals show neutral RSI of 67 and bullish MACD crossover, explaining why NNVC maintains its current current market pressure. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Overbought levels (RSI 67) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.30
Potential Upside
5%
Whystock Fair Value$1.37
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$27.64M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.30
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-75.13%
Volume
Today's trading volume
300,155
Recent News
NanoViricides says NV-387 could address measles outbreaks as cases rise globally
NanoViricides (NYSE-A:NNVC) said on Tuesday its antiviral drug candidate NV-387 could help address rising measles cases globally, citing recent outbreaks and unmet treatment needs. The company pointed to data from Bangladesh showing 18,219 suspected measles cases over the last month, with...
NanoViricides seeks FDA’s rare pediatric disease designation for antiviral candidate NV-387 - ICYMI
NanoViricides (NYSE-A:NNVC) CEO Dr. Anil Diwan talked with Proactive about the company’s recent FDA application for rare pediatric disease designation for its antiviral candidate NV-387, highlighting both the scientific and commercial implications of the move. Diwan explained that the...
NanoViricides files for Rare Pediatric Disease Designation for Measles Drug
NanoViricides CEO Dr Anil Diwan joined Steve Darling from Proactive to announce that the company has filed an application for Rare Pediatric Disease Drug Designation with the U.S. FDA’s Office of Orphan Products Development for NV-387 as a treatment for measles. The RPDD application is expected to be combined with the company’s previously submitted Orphan Drug Designation application for NV-387, filed in February 2026, as part of a broader regulatory strategy to advance the drug candidate. If granted, the designation would make NanoViricides eligible for a Priority Review Voucher upon approval of NV-387. PRVs are tradable assets that have recently commanded values of approximately $160 million, reflecting their ability to accelerate regulatory review timelines for other drugs. Diwan emphasized the potential impact of NV-387, stating the therapy could become an important tool in addressing the resurgence of measles in the United States and globally. He added that treatment with NV-387 may support rapid recovery while helping to reduce complications, including the rare but serious post-measles “immune amnesia” effect. Currently, there are no approved antiviral treatments specifically for measles, highlighting a significant unmet medical need. The Rare Pediatric Disease Priority Review Voucher program was reauthorized in February 2026 under the Consolidated Appropriations Act, reinforcing incentives for companies developing therapies targeting serious pediatric conditions. Measles cases have been rising in the United States, with more than 1,600 laboratory-confirmed cases reported across 33 states as of early April 2026, according to the CDC. While hospitalization rates have declined compared to 2025, the disease continues to pose risks, particularly among pediatric populations, which account for approximately 70% of cases. #proactiveinvestors #nanoviricidesinc #nyseamerican #nnvc #measles #nanoviricides #NV387 #OrphanDrugDesignation #AntiviralTherapy #ClinicalTrials #PhaseII #OrphanDrugDesignation #FDA #Measles #Antiviral #HealthcareInnovation #MedicalResearch #Biopharma #PediatricHealth #GlobalHealth
NanoViricides seeks rare pediatric disease status for measles drug NV-387
NanoViricides (NYSE-A:NNVC) said on Tuesday it has filed an application with the US Food and Drug Administration for Rare Pediatric Disease Drug designation for its antiviral candidate NV-387 as a treatment for measles. The clinical-stage company said the application, submitted to the FDA’s...
NanoViricides to begin Phase II trial of MPox treatment in Congo
NanoViricides (NYSE-A:NNVC) said on Wednesday it expects to begin a Phase II clinical trial of its antiviral candidate NV-387 for the treatment of mpox in the Democratic Republic of Congo (DRC) shortly. The company said site preparations are underway, led by contract research organization Om...